<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Approximately 5% to 10% of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>) harbor an MYC oncogene rearrangement (MYC+) </plain></SENT>
<SENT sid="1" pm="."><plain>The prognostic significance of MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> was determined in an unselected population of patients with newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> treated with rituximab in combination with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> chemotherapy (R-CHOP) </plain></SENT>
<SENT sid="2" pm="."><plain>Using a Vysis break-apart fluorescence in situ hybridization probe, 12 of 135 (8.8%) cases of MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> were identified that had no defining high-risk features </plain></SENT>
<SENT sid="3" pm="."><plain>MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> was associated with an inferior 5-year progression-free survival (66% vs 31%, P = .006) and overall survival (72% vs 33%, P = .016) </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariate analysis confirmed the prognostic importance of MYC for both progression-free survival (hazard ratio = 3.28; 95% confidence interval, 1.49-7.21, P = .003) and overall survival (hazard ratio = 2.98; 95% confidence interval, 1.28-6.95, P = .011) </plain></SENT>
<SENT sid="5" pm="."><plain>Cases of MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> also had a higher risk of central <z:mp ids='MP_0008912'>nervous</z:mp> system relapse (P = .023), independent of other risk factors </plain></SENT>
<SENT sid="6" pm="."><plain>The diagnosis of MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In the R-CHOP treatment era, MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> have an inferior prognosis </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment regimens similar to those used in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> may be more appropriate in this patient population and need to be prospectively tested </plain></SENT>
</text></document>